<DOC>
	<DOC>NCT01274182</DOC>
	<brief_summary>The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.</brief_summary>
	<brief_title>GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Rheumatoid arthritis as defined by the 1987 ACR classification Severe active seropositive disease Inadequate response or intolerance to other DMARDs and antiTNFs Treatment with Methotrexate Patients with systemic manifestations of rheumatoid arthritis Female patients nursing Women of childbearing potential unless using birth control Active infection Known immunodeficiency syndrome Positive Hepatitis B surface antigen or antibodies to Hepatitis C History of cancer Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>